Service Models
License Model
Under this model, clients acquire a license to purchase SXCsoftware applications, bringing management of their drug benefit plans, and of those applications, in-house. SXC also receives an annual maintenance fee for application upgrades and customer support. The customer profile for the license model is typically a large health plan with the infrastructure to manage both drug benefit plans and IT resources in-house.
ASP Transaction Model
This model leverages our data center operations and RxCLAIM® transaction processing engine. Customers pay SXC on a per transaction basis, with the fee contingent on the number of pharmacy benefit management services they contract for. This model is well suited to small- and mid-size PBMs and health plans.
Private Label PBM
As its name indicates, this model is suited to small and mid-sized PBMs looking to outsource the development and maintenance of the technological infrastructure required to deliver PBM services. SXC will provide prescription drug adjudication services via its data center along with a host of other pharmacy benefit services which are branded to health plan members as the PBM’s own.
à la Carte PBM Service
SXC’s PBM services can be sold as a complete package or on an individual basis. The flexibility to purchase these services individually is attractive to employer groups, government agencies and long-term care operators. These organizations typically manage a portion of their pharmacy benefit plans in-house, but look to SXC for outsourcing of one or more functions.
Full Service Model
Branded as informedRx®, our full-service model enables clients to gain complete control of their pharmacy benefit programs — with total and complete financial transparency — and maximize cost control and quality of care through a full range of pharmacy benefit management services.

Valued Partnerships
Department of Health and Human Services projects U.S. prescription drug spending to increase from $200.7 billion in 2005 to $497.5 billion in 2016, a 148% increase in 11 years.
– Kaiser Family
Foundation
Prescription Drug
Trends Fact Sheet,
May 2007
–John Romza
Executive Vice President Research and Development / CTO